Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives

Dow Jones

2024/12/27

By Stephen Nakrosis

Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options.

The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday.

The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding.

In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma.

After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 26, 2024 17:02 ET (22:02 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2494135808"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494135808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494135808?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494135808","market":"sg","top_or_hot":-1,"title":"Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n</p>\n<p>\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n</p>\n<p>\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n</p>\n<p>\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-27 06:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n</p>\n<p>\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n</p>\n<p>\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n</p>\n<p>\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494135808","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494135808","pubTimestamp":1735250520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options.The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday.The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding.In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma.After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Viracta Therapeutics结束Naval-1临床试验，正在探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VIRX":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n\n\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n\n\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n\n\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n\n\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2024 17:02 ET (22:02 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}